Aldeyra Therapeutics (ALDX) Gets a Buy Rating from JonesTrading

JonesTrading analyst Prakhar Agrawal maintained a Buy rating on Aldeyra Therapeutics (ALDXResearch Report) today and set a price target of $20.00. The company’s shares closed last Thursday at $12.13.

According to TipRanks.com, Agrawal is a 2-star analyst with an average return of 9.7% and a 71.4% success rate. Agrawal covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Phathom Pharmaceuticals, and Arena Pharma.

Currently, the analyst consensus on Aldeyra Therapeutics is a Strong Buy with an average price target of $25.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.62 and a one-year low of $1.48. Currently, Aldeyra Therapeutics has an average volume of 1.1M.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALDX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.